Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

February 27, 2014

Las Vegas, Nevada

Continuing Medical Education


Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this live educational activity for a maximum 4.5 of AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for medical oncologists, hematologists, and other health-care professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians' assistants, etc.) involved and/ or interested in the therapeutic management of patients with hematologic malignancies and benign hematologic disorders.

Objectives

After successfully completing this continuing medical education activity, participants should be able to:

  • Summarize new insights into the biology of hematologic malignancies, benign hematologic disorders, and explain how these findings are being used to develop new and improved treatment strategies
  • Review the latest clinical trial updates on new and emerging therapies for hematologic malignancies and benign hematologic disorders, and discuss issues in incorporating these agents into clinical practice
  • Incorporate novel tools and strategies for diagnosis, prognosis, and risk stratification into management of hematologic malignancies and benign hematologic disorders
  • Consider various patient subgroups (younger, elderly, newly diagnosed, relapsed, treatment-refractory, etc.) when formulating treatment algorithms for patients with hematologic malignancies and benign hematologic disorders
  • Discuss major findings and expert perspectives presented at ASH 2013 and their potential impact on current clinical guidelines and standards of care